
Commentary|Videos|December 9, 2025
Dr Leslie on Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma
Author(s)Lori A. Leslie, MD
Fact checked by: Ashling Wahner , Chris Ryan
Lori A. Leslie, MD, discusses 3-year efficacy findings with epcoritamab plus rituximab and lenalidomide in previously untreated follicular lymphoma.
Advertisement
“Time-limited epcoritamab with [lenalidomide plus rituximab] resulted in durable responses that were deep, with an overall response rate of 95% and a complete response rate of 88%.”
Lori A. Leslie, MD, director of the Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs at John Theurer Cancer Center at Hackensack Meridian Health and an assistant professor at the Hackensack Meridian School of Medicine, discussed 3-year efficacy findings from arm 6 of the phase 1b/2 EPCORE NHL-2 trial (NCT04663347) investigating epcoritamab-bysp (Epkinly) plus rituximab (Rituxan) and lenalidomide (Revlimid) in patients with previously untreated follicular lymphoma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5




































